Taiwan Liposome Company (TLC) is a clinical-stage specialty pharmaceutical company dedicated to the development and commercialization of novel nanomedicines that combine their proprietary lipid-assembled drug delivery platform with approved active pharmaceutical ingredients (APIs). Their extensive experience with liposome science could enable them to combine onset speed and benefit duration, and to improve API concentrations at target tissues while decreasing unwanted systemic exposures. Their BioSeizer lipid formulation technology enables local sustained release of APIs at the site of disease or injury and is utilized in their TLC599, TLC590 and TLC399 programs. TLC’s NanoX targeted delivery technology enables prolonged pharmacokinetic (PK) profiles and enhanced distribution of liposome-encapsulated APIs at the desired site and is utilized in their TLC178 program. Their technologies can be used with a broad range of APIs and enable a simplified and scalable manufacturing process. Since their product candidates use already approved APIs, they are eligible to use 505(b)(2) regulatory pathway for approval in the US. They have used their proprietary technology platforms to assemble a diverse product candidate portfolio that targets significant areas of unmet medical need in pain management, ophthalmology and oncology.